What is Fanconi Anemia

TL;DR: Fanconi Anemia is a rare, inherited genetic disorder characterized by bone marrow failure, physical abnormalities, and an increased risk of developing certain cancers, particularly leukemia and squamous cell carcinomas. It is caused by mutations in genes responsible for DNA repair, leading to genomic instability that affects multiple organ systems throughout the body.

What is Fanconi Anemia?

Fanconi Anemia is a complex multisystem disorder that primarily impacts the body's ability to repair damaged DNA. Because the cellular "machinery" responsible for fixing DNA errors is faulty, patients with Fanconi Anemia experience increased sensitivity to DNA-damaging agents. This leads to a progressive decline in bone marrow function—the tissue responsible for creating blood cells—which is often the most critical clinical challenge. Currently, 125 people with Fanconi Anemia are part of the DiseaseMaps community, sharing their experiences to help others navigate this rare diagnosis.

Which body systems are affected by Fanconi Anemia?

The effects of Fanconi Anemia are systemic, meaning they can manifest in several ways across different organ systems. While every individual’s experience is unique, common clinical features include:

• Hematologic: Bone marrow failure, leading to low counts of red blood cells (anemia), white blood cells (leukopenia), and platelets (thrombocytopenia).


• Physical Development: Short stature, skeletal abnormalities (often involving the thumbs or forearms), and microcephaly (smaller than average head size).


• Sensory and Internal: Hearing loss, eye abnormalities, and structural differences in the kidneys or heart.


• Oncological: A significantly elevated predisposition to developing cancers, most notably acute myeloid leukemia (AML) and head and neck squamous cell carcinomas.

How common is this condition and who does it affect?

Fanconi Anemia is a rare condition with an estimated birth prevalence of approximately 1 in 100,000 to 250,000 individuals worldwide. However, the prevalence is notably higher in specific populations, such as Ashkenazi Jewish, Afrikaner, and Spanish Gypsy communities, due to founder effects. The condition typically presents in childhood, with the median age of onset for hematologic symptoms occurring between 5 and 10 years of age. There is no significant difference in gender distribution; Fanconi Anemia affects males and females equally across all geographic regions.

What causes Fanconi Anemia?

At the molecular level, Fanconi Anemia is caused by mutations in one of at least 23 different genes (such as FANCA, FANCC, and FANCG). These genes work together in a pathway to repair interstrand crosslinks in DNA. When this pathway fails, cells cannot properly replicate or repair their genetic material, leading to cell death or mutations that drive cancer. It is primarily inherited in an autosomal recessive pattern, meaning a child must inherit two mutated copies of the gene—one from each parent—to develop the disease.

How does Fanconi Anemia differ from other blood disorders?

While Fanconi Anemia shares symptoms with other bone marrow failure syndromes (like Aplastic Anemia or Diamond-Blackfan Anemia), it is distinct due to the underlying DNA repair defect. A key clinical test used to differentiate Fanconi Anemia is the chromosomal breakage test, which exposes a patient's white blood cells to DNA-damaging agents; cells with the disorder show a characteristic pattern of chromosome breakage that is not typically seen in other blood conditions.

Next steps

• Consult a hematologist or a geneticist specializing in bone marrow failure syndromes for specialized testing.


• Connect with the 125 members of the DiseaseMaps Fanconi Anemia community to share insights and find emotional support.


• Reach out to organizations like the Fanconi Anemia Research Fund for the latest information on clinical trials and research.


• Ensure that you are receiving care at a center of excellence familiar with the unique surveillance protocols required for Fanconi Anemia patients.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.

References

• NIH GARD: Fanconi Anemia Information Page


• Orphanet: Fanconi Anemia Overview (ORPHA:84)


• OMIM: Fanconi Anemia, Complementation Group A


• Fanconi Anemia Research Fund: Comprehensive Patient Resources